Jazz Stock Hits New 52-Week High (JAZZ)

NEW YORK ( TheStreet) -- Jazz Pharmaceuticals (Nasdaq: JAZZ) hit a new 52-week high Friday as it is currently trading at $72.39, above its previous 52-week high of $72.24 with 291,091 shares traded as of 11:50 a.m. ET. Average volume has been 968,800 shares over the past 30 days.

Jazz has a market cap of $4.09 billion and is part of the health care sector and drugs industry. Shares are up 30.9% year to date as of the close of trading on Wednesday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Jazz as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. You can view the full Jazz Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more..